Parainfluenza Virus Human IgA Assay Control BC126A

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Parainfluenza Virus Human IgA Assay Control, recombinant
Applications: ELISA
Suitable for IgA detection
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC126A Category: Virion/Serion kits Tags: ELISA control serum, IgA, Parainfluenza Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Parainfluenza Virus reactive IgA
species reactivity	Parainfluenza Virus
applications	ELISA
assay type	Indirect & quantitative
available size	1 mL

Parainfluenza Virus Human IgA Assay Control BC126A

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Form liquid
Associated products Parainfluenza Virus Type 1 Antigen (BA1261VS) Parainfluenza Virus Type 2 Antigen (BA1262VS) Parainfluenza Virus Type 3 Control Antigen (BA1263VS) Parainfluenza Virus Human IgA Assay Control (BC126A) Parainfluenza Virus Human IgG Assay Control (BC126G) Parainfluenza Virus IgA ELISA Kit (ESR126A) Parainfluenza Virus IgG ELISA Kit (ESR126G)

target relevance

human antibody anti-Parainfluenza Virus

Parainfluenza Virus

Description
Virus that causes upper and lower respiratory tract infections, including croup

Structure
Human parainfluenza viruses (HPIVs) are enveloped, negative-sense, single-stranded RNA viruses belonging to the family Paramyxoviridae. Four major types, HPIV-1, HPIV-2, HPIV-3, and HPIV-4, are recognized as important human respiratory pathogens. The viral envelope contains hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins that facilitate attachment to and entry into host respiratory epithelial cells. Human parainfluenza viruses are distributed worldwide and are among the most common causes of respiratory tract infections in infants and young children, although reinfections frequently occur throughout life. HPIV-1 and HPIV-2 are particularly associated with croup, while HPIV-3 is a major cause of bronchiolitis and pneumonia. The viruses are transmitted through respiratory droplets, direct contact with respiratory secretions, and contaminated surfaces.

Diagnosis
The diagnosis of parainfluenza virus infection is performed through molecular, antigen detection, and serological methods. Reverse transcription polymerase chain reaction (RT-PCR) is the preferred diagnostic method due to its high sensitivity and specificity and is commonly included in multiplex respiratory pathogen panels. Viral RNA can be detected in nasopharyngeal swabs, throat swabs, and other respiratory specimens. Antigen detection assays and direct immunofluorescence tests may provide more rapid results but generally have lower sensitivity than molecular methods. Viral culture may be used in specialized laboratories, while serological assays are primarily utilized for epidemiological studies and research purposes. Laboratory confirmation is particularly useful in hospitalized patients, immunocompromised individuals, and outbreak investigations.

Symptoms
Parainfluenza virus infections typically develop following an incubation period of approximately two to seven days. Clinical manifestations vary according to patient age, immune status, and viral type. Common symptoms include fever, runny nose, nasal congestion, sore throat, cough, hoarseness, and malaise. In young children, parainfluenza viruses are a leading cause of croup, characterized by a distinctive barking cough, inspiratory stridor, and respiratory distress due to inflammation of the upper airway. Lower respiratory tract involvement may result in bronchiolitis, bronchitis, or pneumonia, particularly in infants, elderly individuals, and immunocompromised patients. While most infections are self-limiting, severe respiratory disease may occur in vulnerable populations and occasionally requires hospitalization.

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Parainfluenza Virus Human IgA Assay Control BC126A?

The Parainfluenza Virus Human IgA Assay Control BC126A should be stored refrigerated at 2-8°C to maintain stability and performance.

Is the Parainfluenza Virus Human IgA Assay Control BC126A compatible with SERION ELISA assays for IgA detection?

Yes, this assay control is ready-to-use and pre-diluted specifically for use with SERION ELISA classic and SERION ELISA antigen assays targeting IgA antibodies.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC126A protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Parainfluenza Virus Human IgA Assay Control BC126A

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Candida albicans IgA Control Serum BC117A

Yersinia IgA Control Serum BC138A

Campylobacter jejuni IgA Control Serum BC139A

Varicella-Zoster Virus IgA Control Serum BC104A

Brucella IgA Control Serum BC116A

Respiratory Syncytial Virus IgA Control Serum BC113A

Bordetella pertussis IgA Control Serum BC120A

Mycoplasma pneumoniae IgA Control Serum BC127A

Adenovirus IgA Control Serum BC128A

Helicobacter pylori IgA Control Serum BC118A

Enterovirus IgA Control Serum BC133A

Echovirus IgA Control Serum BC135A

Coxsackie IgA Virus Control Serum BC134A

Chlamydia trachomatis IgA Control Serum BC1372A

Chlamydia pneumoniae IgA Control Serum BC1371A